Welcome to our dedicated page for Marpai news (Ticker: MRAI), a resource for investors and traders seeking the latest updates and insights on Marpai stock.
Marpai, Inc. (MRAI) is a technology platform company whose subsidiaries provide Third-Party Administration (TPA), Pharmacy Benefit Management (PBM) and value-oriented health plan services to employers that directly pay for employee health benefits. This news page aggregates company-issued updates and related coverage so readers can follow how Marpai describes its progress in the self-funded employer health plan market.
Recent Marpai news has focused on its turnaround strategy, cost discipline and operational efficiency, as well as developments in its TPA and PBM offerings. The company has reported reductions in operating expenses and changes in operating loss and net loss over multiple quarters, and it links these trends to efforts to streamline operations and adjust its business model. News releases also highlight private placements and other capital transactions disclosed in Form 8-K filings, which Marpai states are intended to support working capital and general corporate purposes.
Marpai’s updates describe initiatives such as the Marpai Saves program and the relaunch of MarpaiRx, its PBM solution, which the company positions as part of its approach to serving self-funded employer health plans. Other announcements discuss network access agreements, including access to the Aetna Signature Administrator PPO network, and the addition of tools like the Aetna Faircost Optimizer for managing out-of-network claims costs.
Investors and observers can use this news feed to review Marpai’s own descriptions of its financial results, strategic initiatives, technology platform developments and capital raising activities. For a fuller picture, readers may compare these news items with the company’s SEC filings and other official disclosures.
Marpai (OTCQX:MRAI) announced two strategic MarpaiRx client wins on Feb 23, 2026, adding >19,000 covered lives and accelerating platform expansion.
Both implementations are expected to be fully operational early in Q2 2026, expand rebate management and TPA services, and reinforce adoption by health plan consultants and brokers.
Marpai (OTCQX: MRAI) announced the hire of Mimi Davis as President of MarpaiRx on January 27, 2026. Davis joins from Knipper Health, bringing prior leadership at Eagle Pharmacy and extensive experience in Pharmacy Benefit Management and retail pharmacy operations. She will oversee strategic expansion, operational scaling, and efforts to streamline pharmacy operations while enhancing MarpaiRx's value proposition. Management says Davis will support growth and integration of Marpai's technology and clinical insights to deliver cost-effective pharmacy benefits to members and clients.
Marpai (OTCQX: MRAI) announced renewal of its access to the Aetna Signature Administrator (ASA) PPO network and integration of the Aetna Faircost Optimizer, while reporting a better-than-expected 2026 sales cycle with new clients effective January 1, 2026. The ASA renewal preserves broad national provider access and competitive network discounts for Marpai's self-funded employer clients, maintaining continuity of care. The Faircost Optimizer adds an integrated tool to manage out-of-network claims and limit balance-billing exposure. Management describes the combination of enhanced network access and cost-containment tools as reinforcing Marpai's path to scalable growth and previously guided profitability targets for 2026.
Marpai (OTCQX:MRAI) reported third quarter 2025 results showing continued turnaround progress and positioning for growth in 2026. For the quarter ended September 30, 2025 the company reported a 24% reduction in operating expenses (from $5.0 to $3.8, ~ $1.2 million saved), a 9% narrower operating loss (from $3.1 million to $2.8 million), and a 2% improvement in net loss (from $3.6 million to $3.5 million). EPS improved by $0.10. Marpai closed a $3.9 million PIPE to support the turnaround and noted double‑digit new clients contracted for January 1. Management reiterated a target of achieving profitability in Q1 2026 and highlighted automation, PBM integration, and claims management as strategic priorities.
Marpai (OTCQX: MRAI) will host a conference call and webcast on Thursday, November 13, 2025 at 8:30 a.m. ET to discuss third quarter 2025 operational and financial highlights. The company will report Q3 2025 results on the Wednesday after market close prior to the call. Investors can join by phone (US: 1-646-357-8785; Toll Free: 1-800-836-8184) or via webcast at https://app.webinar.net/934VMynbB6a. A replay will be available at the same webcast URL within two hours after the call and by phone through November 20, 2025 using replay code 79452#.
Marpai (OTCQX: MRAI) was recognized as a Top Health Plan Third Party Administrator for 2025 by Insurance Business Review Magazine on October 14, 2025.
The award cites Marpai's technology-driven model emphasizing Smarter Tools, Better Care, and Real Savings, its focus on anticipating high-cost events, and its role beyond claims processing in the $150 billion TPA sector. The selection followed nominations and an evaluation by an expert panel of C-level executives, industry leaders, and the magazine's editorial board. Management said the accolade validates the company’s innovation and value proposition for clients and members.
Marpai (OTCQX: MRAI) announced a private placement on Oct 6, 2025 raising approximately $200,000 from HillCour Investment Fund, an entity controlled by CEO Damien Lamendola. The purchase comprised 147,058 shares at $1.36 per share. The company said net proceeds will be used for general corporate purposes, including accelerating product deployment, enhancing its technology platform, and deepening market penetration among self-funded employer groups. Marpai reported a total of $1.7 million raised in Q3 2025. The placement relied on exemptions under Section 4(a)(2) and Regulation D and is not an offer to sell publicly.
Marpai (OTCQX: MRAI), a healthcare technology and TPA services provider, reported significant improvements in its Q2 2025 financial results, marking substantial progress in its turnaround strategy. The company achieved a 70% reduction in operating expenses, saving $9.9 million, and reduced its operating loss by 71% to $3.6 million.
Net loss decreased by 66% to $4.4 million, with net loss per share improving by $0.95. However, net revenues declined by $2.5 million to $4.7 million compared to the same quarter last year. CEO Damien Lamendola expressed confidence in achieving profitability by Q1 2026, citing a strong pipeline of new business and planned infrastructure investments in Q3 2025.
Marpai (OTCQX: MRAI), a healthcare technology and Third-Party Administration (TPA) services provider, has scheduled its Q2 2025 earnings conference call for August 14, 2025, at 8:30 a.m. ET. The company will release its second quarter 2025 financial results after market close on August 13.
Investors can access the call via phone at 1-800-836-8184 (toll-free) or 1-646-357-8785, and through webcast at https://app.webinar.net/pD32GbLd5Mx. A replay will be available for one week until August 21, 2025, using replay code 02046.
Marpai (OTCQX: MRAI) has announced the comprehensive relaunch of MarpaiRx, a revolutionary pharmacy benefit management (PBM) solution targeting the $150 billion TPA market. The program, set to launch in H2 2025, aims to transform traditional PBM services with complete transparency and significant cost reductions.
MarpaiRx's key features include no hidden spreads or markups, real-time prescription optimization, integrated patient assistance programs, and international sourcing options. The platform tackles high specialty drug costs through a multi-pronged approach, including lowest net cost optimization and flexible copay programs. The solution leverages advanced technology for real-time analysis and seamless integration with existing health IT systems.